<DOC>
	<DOCNO>NCT01453049</DOCNO>
	<brief_summary>The purpose study demonstrate rosiglitazone/glimepiride fixed-dose combination tablet safely effectively control glycemia first-line oral therapy drug naïve subject type 2 diabetes . This 24-week study compare effect treatment rosiglitazone/glimepiride treatment glimepiride alone . The primary objective demonstrate superiority rosiglitazone/glimepiride glimepiride lower Glycosylated Hemoglobin ( HbA1c ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Fixed-dose Rosiglitazone/Glimepiride Treat Chinese Type 2 Diabetes Patients</brief_title>
	<detailed_description>The antihyperglycemic effect thiazolidinedione ( TZD ) class oral antidiabetic agent due ability increase insulin sensitivity cellular level , turn improve ability endogenous insulin regulate glucose utilization tissue . Compounds sulfonylurea ( SU ) class act stimulate insulin production pancreas , overcome insulin resistance increase circulate insulin level . The mechanisms two kind OADs may view complementary , offer opportunity improve efficacy durability effect coadministration TZD sulfonylurea . Successful management type 2 diabetes mellitus ( T2DM ) require aggressive glycemic control start early stage disease . Rosiglitazone/glimepiride combination therapy , complementary mechanism action , potential provide significant benefit monotherapy first line therapy . Treatment rosiglitazone/glimepiride early stage diabetes expect provide good glycemic control allow great proportion patient achieve target glycemic goal oral monotherapy . This multicenter , randomize , double-blinded , parallel , study compare effect treatment rosiglitazone/glimepiride combination glimepiride drug naïve T2 DM patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>type 2 diabetes mellitus HbA1c 7.5 % 11.0 % screen FPG 7.0mmol/L 13.3mmol/L screen randomization visit subject treat diet and/or exercise alone QTc &lt; 450mesc QTc &lt; 480msec patient bundle branch block Body Mass Index ( BMI ) &gt; 19kg/m2 Subject give write informed consent Documented history significant hypersensitivity thiazolidinediones , sulfonylurea , compound similar chemical structure Ongoing edema history edema require pharmacological treatment 12 month prior screen Presence ischemic heart disease and/or peripheral arterial disease , NYHA grade IIV congestive heart failure Taking nitrate Clinically significant renal hepatic disease Anemia Severe hypertriglyceridemia ( TG &gt; =5.65mmol/L ) Use oral corticosteroid Nicotinic acid Systolic blood pressure &lt; 170mmHg , diastolic blood pressure &gt; 100mmHg antihypertensive treatment Hyperthyroidism require treatment Diagnosed macular edema Women lactating , pregnant , plan become pregnant Presence active cancer recently treat cancer Drug/alcohol abuse Unwilling unable comply procedure describe protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>rosiglitazone/glimepiride , fix dose , type 2 diabetes</keyword>
</DOC>